Diabetic peripheral neuropathy: Current perspective and future directions

Singh, Randhir; Kishore, Lalit; Kaur, Navpreet

doi:10.1016/j.phrs.2013.12.005

Cited by 311 publications

(243 citation statements)

References 191 publications

Supporting

Mentioning

224

Contrasting

Unclassified

Order By: Relevance

“…The pathogenesis of DPN remains uncertain, and its mechanism is complex and multi-factorial. At present, no specific medication is available for DNP treatment [7,9,10].…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia

Xuan

Zhao

et al. 2017

Purinergic Signalling

View full text Add to dashboard Cite

Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus (DM). More than 90% of all cases of DM belong to type 2 diabetes mellitus (T2DM). Emodin is the main active component of Radix et rhizoma rhei and has anti-bacterial, anti-viral, anti-ulcerogenic, anti-inflammatory, and anti-cancer effects. Nanoparticle encapsulation of drugs is beneficial for drug targeting and bioavailability as well as for lowering drug toxicity side effects. The aim of this study was to investigate the effects of nanoparticleencapsulated emodin (nano emodin) on diabetic neuropathic pain (DNP) mediated by the Purin 2X3 (P2X3) receptor in the dorsal root ganglia (DRG). Mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) values in T2DM rats were lower than those of control rats. MWT and TWL in T2DM rats treated with nano emodin were higher compared with those in T2DM rats. Expression levels of P2X3 protein and messenger RNA (mRNA) in the DRG of T2DM rats were higher than those of controls, while levels in T2DM rats treated with nano emodin were significantly lower than those of the T2DM rats. Phosphorylation and activation of ERK1/2 in the T2DM DRG were decreased by nano emodin treatment. Nano emodin significantly inhibited currents activated by the P2X3 agonist α,β-meATP in HEK293 cells transfected with the P2X3 receptor. Therefore, nano emodin treatment may relieve DNP by decreasing excitatory transmission mediated by the DRG P2X3 receptor in T2DM rats.

show abstract

“…The pathogenesis of DPN remains uncertain, and its mechanism is complex and multi-factorial. At present, no specific medication is available for DNP treatment [7,9,10].…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia

Xuan

Zhao

et al. 2017

Purinergic Signalling

View full text Add to dashboard Cite

show abstract

“…Increasing evidence indicated that hyperglycemia played a key role in the development and progression of diabetic neuropathy (Singh et al, 2014). Hyperglycemia induces oxidative stress to generate reactive oxygen species and reactive nitrogen species in diabetic neurons resulting in neuronal damage and dysfunction (Vincent et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

Protective effect of HAMI 3379 against high glucose-induced PC12 cell injury

Chunzhen¹,

Wang²,

Li³

2015

Res. Pharm. Biotech.

View full text Add to dashboard Cite

Diabetic neuropathy is one of the most common diabetic complications, associated with long time exposure to high glucose. Hyperglycemia induces the production of reactive oxygen species (ROS) and reactive nitrogen species contributing to neuronal damage. We have previously reported that HAMI 3379, a selective antagonist of CysLT 2 receptor, is involved in neuron injury after ischemia. In this study, we investigated the protective effect of HAMI 3379 against high glucose-induced cell injury in PC12 neural cells. The PC12 cells were pretreated with various concentrations of HAMI 3379 (0.001 ~ 10 µM) for 1 h and then co-treated with HAMI 3379 and D-glucose (100 mM) for 48 h. HAMI 3379 (0.001 ~ 10 µM) protected PC12 cells against high glucose toxicity, as determined by cell viability and apoptosis after the evaluation by Hoechst 33342 staining assay. In addition, the increased nitric oxide production and nitric oxide synthase (NOS) activity in the media induced by high glucose was significantly inhibited by HAMI 3379. These results demonstrate that HAMI 3379 protected PC12 cells against high glucoseinduced neurotoxicity by inhibition of apoptosis, nitric oxide production and nitric oxide synthase activity, suggesting that CysLT 2 receptor may be a potential target for diabetic neuropathy, and its antagonist may play a crucial role in the treatment of diabetic neuropathy.

show abstract

“…However, there are many research initiatives exploring several pathways to develop such treatments. 20 Any treatment would profit from early detection based on reliable screening tools. Furthermore, although there are several studies comparing various screening methods in adults with diabetes, a recent review of the diagnostic utility of monofilament tests also identified 3 studies that have methodologic problems similar to those that were reported here.…”

Section: Discussionmentioning

confidence: 99%

Screening for Peripheral Neuropathies in Children With Diabetes: A Systematic Review

et al. 2014

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVE: Although guidelines for the management of children with type 1 diabetes include recommendations to screen for diabetic peripheral neuropathies (DPN), the research into the diagnostic utility of screening methods has not been systematically reviewed. The goal of this study was to summarize the findings with regard to the diagnostic accuracy of the Semmes-Weinstein monofilament and the Rydel-Seiffer tuning fork in detecting DPN in children and adolescents compared with the gold standard nerve conduction studies. METHODS:Based on a PubMed search (conducted on April 26, 2013) and secondary searching, we identified 72 articles for review. We included studies that: (1) assessed DPN with the gold standard nerve conduction studies; (2) used noninvasive screening for DPN (monofilament, tuning fork, or biothesiometer); and (3) were performed in the relevant population (children with diabetes). Five articles met these criteria. Study quality was assessed by using the revised Quality Assessment of Diagnostic Accuracy Studies criteria. Heterogeneous methods precluded a formal meta-analysis of effects.RESULTS: Diagnostic accuracies were heterogeneous for the different screening methods. Sensitivities ranged from 1% to 19% for the tuning fork (3 studies); from 61% to 80% for the biothesiometer (2 studies); and from 19% to 73% for the monofilament (2 studies).CONCLUSIONS: Data show extremely low diagnostic utility for standard screening methods (tuning fork and 10-g monofilament) but acceptable utilities for biothesiometry and finer (1 g) monofilaments. Data on the diagnostic utility should be used to inform national and international guidelines on diabetes management.

show abstract

Diabetic peripheral neuropathy: Current perspective and future directions

Cited by 311 publications

References 191 publications

Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia

Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia

Protective effect of HAMI 3379 against high glucose-induced PC12 cell injury

Screening for Peripheral Neuropathies in Children With Diabetes: A Systematic Review

Contact Info

Product

Resources

About